Danazol for the Treatment of Idiopathic Thrombocytopenic Purpura

New England Journal of Medicine

Volumn 308, Issue 23, 1983, Pages 1396-1399

  Ahn, Yeon S ^a,b   Harrington, William J ^a,b   Simon, Sheryl R ^a,b   Mylvaganam, Ravindra ^a,b   Pall, Lorraine M ^a,b   so, Antero G ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; DANAZOL; HYDROCORTISONE; IMMUNOGLOBULIN; VINCA ALKALOID;

AUTOIMMUNE DISEASE; BLOOD AND HEMOPOIETIC SYSTEM; CLINICAL ARTICLE; DRUG EFFICACY; DRUG THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; REMISSION; THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0020636872     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198306093082306     Document Type: Article

References (30)

1. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1–10.
2. Harrington WJ, Sprague CC, Minnich V, Moore CV, Aulvin RC, Dubach R. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433–69.
3. Harrington WJ, Minnich V, Arimura G. The autoimmune thrombocytopenias. Prog Hematol 1956; 1: 166–92.
4. Shulman NR, Marder VJ, Weinrach RS. Similarities between known anti-platelet antibodies and the factor responsible for thrombocytopenia in idiopathic thrombocytopenic purpura: physiologic, serologic, and isotopic studies. Ann NY Acad Sci 1965; 124: 499–542.
5. Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980: 56: 329–43.
6. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304: 1135–47.
7. Ahn YS, Harrington WJ. Treatment of idiopathic thrombocytopenic purpura (ITP). Annu Rev Med 1977; 28: 299–309.
8. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med 1974; 291: 376–80.
9. Ahn YS, Byrnes JJ, Harrington WJ, et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N Engl J Med 1978; 298: 1101–7.
10. Ahn YS, Harrington WJ. Clinical uses of macrophage inhibitors. Adv Intern Med 1980; 25: 453–73.
11. Branda RF, Tate DY, McCullough JJ, Jacob HS. Plasma exchange in the treatment of fulminant (autoimmune) thrombocytopenic purpura. Lancet 1978; 1: 688–90.
12. Marder VJ, Nusbacher J, Anderson FW. One-year follow-up of plasma exchange therapy in 14 patients with thrombocytopenic purpura. Transfusion 1981; 21: 291–8.
13. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gamma-globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228–31.
14. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma-globulin. N Engl J Med 1982; 306: 1254–8.
15. Melo J, Harrington WJ, Ahn YS, et al. Colchicine therapy of idiopathic thrombocytopenic purpura (ITP). Blood 1981; 58: Supplement 1: 200a. abstract.
16. Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy of refractory immune thrombocytopenia. Blood 1982; 60: Supplement 1: 193a. abstract.
17. Madanes AE, Farber M. Danazol. Ann Intern Med 1982; 96: 625–30.
18. Pariser K, Gell J, Gelfand J, Turksoy N, Agnello V. Pilot studies in the use of danazol in treatment of patients with systemic lupus erythematosus. Proceedings of the 15th International Congress of Rheumatology, 1981. abstract 483.
19. Harrington WJ, Ahn WS, So AG, et al. Danazol therapy of autoimmune thrombocytopenias. Blood 1982; 60: Supplement 1: 186a. abstract.
20. von dem Borne AEGK, Verheugt FWA, Oosterhof F, von Riesz E, Brutel de la Rivière A, Engelfriet CP. A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978; 39: 195–207.
21. Hosea SW, Santaella ML, Brown EJ, Berger M, Katusha K, Frank MM. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 1980; 93: 809–12.
22. Gadek JE, Fulmer JD, Gelfand JA, Frank MM, Petty TL, Crystal RG. Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest 1980; 66: 82–87.
23. Morley KD, Parke A, Hughes GRV. Systemic lupus erythematosus: two patients treated with danazol. Br Med J 1982; 284: 1431–2.
24. Fretwell MD, Altman LC. Exacerbation of a lupus-erythematosus-like syndrome during treatment of non–C1-esterase-inhibitor–dependent angioedema with danazol. J Allergy Clin Immunol 1982; 69: 306–10.
25. Roubinian JR, Papoian R, Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 1977; 59: 1066–70.
26. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147: 1568–83.
27. Michalski JP, McCombs CC, Roubinian JR, Talal N. Effect of androgen therapy on survival and suppressor cell activity in aged NZB/NZW F1 hybrid mice. Clin Exp Immunol 1983; 52: 229–33.
28. Eidinger D, Garrett TJ. Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med 1972; 136: 1098–116.
29. Barbieri RL, Ryan KJ. Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 1981; 141: 453–63.
30. Wentz achéal. Adverse effects of danazol in pregnancy. Ann Intern Med 1982; 96: 672–3.